Literature DB >> 21685375

Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.

Debasmita Roy1, Sang-Hoon Sin, Blossom Damania, Dirk P Dittmer.   

Abstract

Primary effusion lymphoma (PEL) is a diffuse-large B-cell lymphoma with poor prognosis. One hundred percent of PELs carry the genome of Kaposi sarcoma-associated herpesvirus and a majority are coinfected with Epstein-Barr virus (EBV). We profiled genomic aberrations in PEL cells using the Affymetrix 6.0 SNP array. This identified for the first time individual genes that are altered in PEL cells. Eleven of 13 samples (85%) were deleted for the fragile site tumor suppressors WWOX and FHIT. Alterations were also observed in the DERL1, ETV1, RASA4, TPK1, TRIM56, and VPS41 genes, which are yet to be characterized for their roles in cancer. Coinfection with EBV was associated with significantly fewer gross genomic aberrations, and PEL could be segregated into EBV-positive and EBV-negative clusters on the basis of host chromosome alterations. This suggests a model in which both host genetic aberrations and the 2 viruses contribute to the PEL phenotype.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21685375      PMCID： PMC3158728          DOI： 10.1182/blood-2010-12-323659

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  61 in total

1.  Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma.

Authors:  H Katano; Y Hoshino; Y Morishita; T Nakamura; H Satoh; A Iwamoto; B Herndier; S Mori
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

2.  Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis.

Authors:  G Gaidano; D Capello; A M Cilia; A Gloghini; T Perin; S Quattrone; A Migliazza; F Lo Coco; G Saglio; V Ascoli; A Carbone
Journal:  Genes Chromosomes Cancer       Date:  1999-01       Impact factor: 5.006

3.  The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions.

Authors:  K V Komanduri; J A Luce; M S McGrath; B G Herndier; V L Ng
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-11-01

4.  Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8.

Authors:  A Carbone; A M Cilia; A Gloghini; D Capello; M Todesco; S Quattrone; R Volpe; G Gaidano
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

5.  Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice.

Authors:  C Boshoff; S J Gao; L E Healy; S Matthews; A J Thomas; L Coignet; R A Warnke; J A Strauchen; E Matutes; O W Kamel; P S Moore; R A Weiss; Y Chang
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

6.  Establishment of HHV-8-positive and HHV-8-negative lymphoma cell lines from primary lymphomatous effusions.

Authors:  A Carbone; A M Cilia; A Gloghini; V Canzonieri; C Pastore; M Todesco; M Cozzi; T Perin; R Volpe; A Pinto; G Gaidano
Journal:  Int J Cancer       Date:  1997-11-14       Impact factor: 7.396

7.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Authors:  L Arvanitakis; E A Mesri; R G Nador; J W Said; A S Asch; D M Knowles; E Cesarman
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

8.  The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers.

Authors:  M Ohta; H Inoue; M G Cotticelli; K Kastury; R Baffa; J Palazzo; Z Siprashvili; M Mori; P McCue; T Druck; C M Croce; K Huebner
Journal:  Cell       Date:  1996-02-23       Impact factor: 41.582

9.  Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation.

Authors:  A Matolcsy; R G Nádor; E Cesarman; D M Knowles
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.

Authors:  E Cesarman; P S Moore; P H Rao; G Inghirami; D M Knowles; Y Chang
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113
View more
  43 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.

Authors:  Ajinkya Patil; Mark Manzano; Eva Gottwein
Journal:  Blood       Date:  2018-06-28       Impact factor: 22.113

3.  Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.

Authors:  Matias Mendeville; Margaretha G M Roemer; Mari F C M van den Hout; G Tjitske Los-de Vries; Reno Bladergroen; Phylicia Stathi; Nathalie J Hijmering; Andreas Rosenwald; Bauke Ylstra; Daphne de Jong
Journal:  Blood       Date:  2018-12-03       Impact factor: 22.113

4.  hVps41 and VAMP7 function in direct TGN to late endosome transport of lysosomal membrane proteins.

Authors:  Maaike S Pols; Eline van Meel; Viola Oorschot; Corlinda ten Brink; Minoru Fukuda; M G Swetha; Satyajit Mayor; Judith Klumperman
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 5.  Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.

Authors:  Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2016-09-01       Impact factor: 14.808

6.  Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma.

Authors:  Dongmei Yang; Wuguo Chen; Jie Xiong; Carly J Sherrod; David H Henry; Dirk P Dittmer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-23       Impact factor: 11.205

7.  Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.

Authors:  Jedediah Seltzer; Razia Moorad; Jason M Schifano; Justin T Landis; Dirk P Dittmer
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

8.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

Review 9.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

10.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.